ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

The development of resistance to established antiretroviral agents is a significant concern in patients with HIV infections. Resistance mutations may result from suboptimal exposure to anti-HIV drugs, and their occurrence increases with prolonged treatment; the development of antiretroviral agents that are effective against HIV strains resistant to established agents is therefore critical. Encouraging results from a recent phase II study suggest that the second-generation, nonpeptidic protease inhibitor (PI) tipranavir is effective in highly treatment-experienced patients with HIV infections, including those with resistance to multiple antiretroviral agents. Data presented at the 10th Conference on Retroviruses and Opportunistic Infections [Boston, US; February 2003] showed that 2 weeks' treatment with tipranavir plus ritonavir reduced HIV RNA levels from baseline. An analysis of viral resistance profiles showed that, despite having resistance to other PIs, nearly 70% of clinical isolates from patients enrolled in the study remained susceptible to tipranavir at baseline. Furthermore, tipranavir remained effective against HIV strains with 2-fold reductions in susceptibility to other PIs."This study shows tipranavir is active against HIV that has reduced sensitivity to commercially available protease inhibitors...tipranavir may[therefore]be a promising option for patients who have few or no treatment options because of drug resistance", said presenter Dr Joseph Gathe, from Baylor College of Medicine in Houston, US.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have become the first-line treatment of choice for HIV infections, as clinicians seek long-term therapies that can avoid some of the adverse effects seen with protease inhibitor-based regimens. A general perception exists among clinicians that efavirenz-based highly active antiretroviral therapy (HAART) is superior to nevirapine-based regimens. However, the 2NN study, the first major head-to-head comparison of efavirenz- and nevirapine-based HAART and a regimen containing both NNRTIs, showed that the two agents were equally effective. These data, presented at the 10thConference on Retroviruses and Opportunistic Infections [Boston, US; February 2003] showed that nevirapine- and efavirenz-based regimens were equally effective in reducing viral load and increasing CD4+ cell counts, with comparable rates of treatment failure. Furthermore, there was no significant difference between the two agents in the proportions of patients experiencing serious clinical adverse events."The results of this large, randomized, prospective, multi-center trial clearly demonstrate the comparable efficacy of nevirapine and efavirenz in HIV treatment", said the study's lead investigator, Dr Joep Lange from the Academic Medical Center of the University of Amsterdam, The Netherlands. Interestingly, the regimen containing both efavirenz and nevirapine was the least effective, and was associated with higher incidences of serious adverse events and laboratory abnormalities than those containing efavirenz or nevirapine alone.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS